nefomed süste-/infusioonilahus
medochemie iberia s.a. - nefopaam - süste-/infusioonilahus - 20mg 2ml 2ml 10tk; 20mg 2ml 2ml 5tk
tolvaptan accord
accord healthcare s.l.u. - tolvaptan - ebapiisav adh-i sündroom - diureetikumid, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).
mabron süstelahus
medochemie limited - tramadool - süstelahus - 50mg 1ml 2ml 5tk; 50mg 1ml 2ml 1tk
tramadol krka rektaalsuposiit
krka d.d., novo mesto - tramadool - rektaalsuposiit - 100mg 5tk
clocinol õhukese polümeerikattega tablett
pharmaceutical works polpharma s.a. - tramadool+paratsetamool - õhukese polümeerikattega tablett - 37,5mg+325mg 30tk; 37,5mg+325mg 60tk; 37,5mg+325mg 90tk; 37,5mg+325mg 20tk; 37,5mg+325mg 10tk
tramadol krka kõvakapsel
krka d.d. novo mesto - tramadool - kõvakapsel - 50mg 20tk
tramadol krka suukaudsed tilgad, lahus
krka d.d. novo mesto - tramadool - suukaudsed tilgad, lahus - 100mg 1ml 10ml 1tk
tramadol krka süstelahus
krka d.d. novo mesto - tramadool - süstelahus - 50mg 1ml 2ml 5tk; 50mg 1ml 1ml 5tk
tramadol basi süstelahus
laboratorios basi industria farmaceutica s.a. - tramadool - süstelahus - 50mg 1ml 2ml 50tk
xtandi
astellas pharma europe b.v. - ensalutamiid - eesnäärmevähk - endokriinset ravi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.